{"pmid":32337590,"title":"Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","text":["Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","We profiled the serological responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger antibody responses were observed in critical patients.","Clin Infect Dis","Qu, Jiuxin","Wu, Chi","Li, Xiaoyong","Zhang, Guobin","Jiang, Zhaofang","Li, Xiaohe","Zhu, Qing","Liu, Lei","32337590"],"abstract":["We profiled the serological responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger antibody responses were observed in critical patients."],"journal":"Clin Infect Dis","authors":["Qu, Jiuxin","Wu, Chi","Li, Xiaoyong","Zhang, Guobin","Jiang, Zhaofang","Li, Xiaohe","Zhu, Qing","Liu, Lei"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337590","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cid/ciaa489","keywords":["covid-19","igg","igm","sars-cov-2","serologic responses"],"topics":["Diagnosis"],"weight":1,"_version_":1665264685539131392,"score":8.574329,"similar":[{"pmid":32330303,"title":"Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","text":["Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang","32330303"],"abstract":["Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330303","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25930","keywords":["covid-19","igg","igm","sars-cov-2","diagnosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664996914758680576,"score":194.84361},{"pmid":32267220,"title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","text":["Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.","A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.","Emerg Infect Dis","Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L","32267220"],"abstract":["A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies."],"journal":"Emerg Infect Dis","authors":["Okba, Nisreen M A","Muller, Marcel A","Li, Wentao","Wang, Chunyan","GeurtsvanKessel, Corine H","Corman, Victor M","Lamers, Mart M","Sikkema, Reina S","de Bruin, Erwin","Chandler, Felicity D","Yazdanpanah, Yazdan","Le Hingrat, Quentin","Descamps, Diane","Houhou-Fidouh, Nadhira","Reusken, Chantal B E M","Bosch, Berend-Jan","Drosten, Christian","Koopmans, Marion P G","Haagmans, Bart L"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267220","week":"202015|Apr 06 - Apr 12","doi":"10.3201/eid2607.200841","keywords":["covid-19","elisa","hcov","rbd","sars-cov-2","severe acute respiratory syndrome coronavirus 2","antibodies","coronavirus","coronavirus disease 2019","human coronavirus","neutralization","nucleocapsid protein","receptor-binding domain","respiratory infections","serologic analysis","spike protein","viruses","zoonoses"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664637636039409665,"score":145.80717},{"pmid":32330291,"title":"Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.","text":["Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.","BACKGROUND: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. METHODS: Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab RT-PCR result. RESULTS: The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The ROC performance curves showed area under the curve (AUC) values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. CONCLUSIONS: iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics. This article is protected by copyright. All rights reserved.","J Med Virol","Infantino, M","Grossi, V","Lari, B","Bambi, R","Perri, A","Manneschi, M","Terenzi, G","Liotti, I","Ciotta, G","Taddei, C","Benucci, M","Casprini, P","Veneziani, F","Fabbri, S","Pompetti, A","Manfredi, M","32330291"],"abstract":["BACKGROUND: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading throughout the world. Though molecular diagnostic tests are the gold standard for COVID-19, serological testing is emerging as a potential surveillance tool, in addition to its complementary role in COVID-19 diagnostics. Indubitably quantitative serological testing provides greater advantages than qualitative tests but today there is still little known about serological diagnostics and what the most appropriate role quantitative tests might play. METHODS: Sixty-one COVID-19 patients and 64 patients from a control group were tested by iFlash1800 CLIA analyzer for anti-SARS CoV-2 antibodies IgM and IgG. All COVID-19 patients were hospitalized in San Giovanni di Dio Hospital (Florence, Italy) and had a positive oro/nasopharyngeal swab RT-PCR result. RESULTS: The highest sensitivity with a very good specificity performance was reached at a cutoff value of 10.0 AU/mL for IgM and of 7.1 for IgG antibodies, hence near to the manufacturer's cutoff values of 10 AU/mL for both isotypes. The ROC performance curves showed area under the curve (AUC) values of 0.918 and 0.980 for anti-SARS CoV-2 antibodies IgM and IgG, respectively. CONCLUSIONS: iFlash1800 CLIA analyzer has shown highly accurate results for the anti-SARS-CoV-2 antibodies profile and can be considered an excellent tool for COVID-19 diagnostics. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Infantino, M","Grossi, V","Lari, B","Bambi, R","Perri, A","Manneschi, M","Terenzi, G","Liotti, I","Ciotta, G","Taddei, C","Benucci, M","Casprini, P","Veneziani, F","Fabbri, S","Pompetti, A","Manfredi, M"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330291","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25932","keywords":["coronavirus","humoral immunity","immune responses","sars coronavirus","virus classification"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["San Giovanni","Florence","Italy","analyzer","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664996914776506369,"score":128.91266},{"pmid":32306047,"title":"Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","text":["Antibody Detection and Dynamic Characteristics in Patients with COVID-19.","BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.","Clin Infect Dis","Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li","32306047"],"abstract":["BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays."],"journal":"Clin Infect Dis","authors":["Xiang, Fei","Wang, Xiaorong","He, Xinliang","Peng, Zhenghong","Yang, Bohan","Zhang, Jianchu","Zhou, Qiong","Ye, Hong","Ma, Yanling","Li, Hui","Wei, Xiaoshan","Cai, Pengcheng","Ma, Wan-Li"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306047","week":"202017|Apr 20 - Apr 26","doi":"10.1093/cid/ciaa461","keywords":["covid-19","elisa","sars-cov-2","diagnosis","serological test"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664641855716851712,"score":124.43076},{"pmid":32343415,"title":"Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.","text":["Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SRAS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in non-severe cases. This article is protected by copyright. All rights reserved.","J Med Virol","Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui","32343415"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SRAS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in non-severe cases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343415","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25946","keywords":["antibody","covid-19","igg","immunity","sars-cov-2"],"locations":["Jinan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1665351883825348609,"score":120.72316}]}